Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Endocrine-Related Cancer|October 12, 2021
Inhibition of GATA2 in prostate cancer by a clinically available small moleculeSalma Kaochar, Aleksandra Rusin, Christopher Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Nature Communications|May 11, 2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaFeng Wang, Kiyomi Morita, Courtney D DiNardo, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2014
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complexBin He, Rainer B Lanz, Warren Fiskus, et al.
Pageof 13